Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
Ramon StaegerJulia Martínez GómezPatrick TurkoEgle RamelyteLukas KraehenbuehlValerio Del PreteOmar Hasan AliMitchell Paul LevesqueReinhard DummerMirjam C NägeliJoanna ManganaPublished in: Cancers (2024)
Our study offers real-world insights into the clinical management, treatment patterns, and outcomes of advanced melanoma patients in both the adjuvant and unresectable setting. Early relapses in patients undergoing adjuvant treatment pose a particular challenge but these patients are generally excluded from first-line trials. The approved first-line metastatic treatments are highly effective in the real-world setting with 5-year OS rates around 50%. However, outcomes remain poor for patients with brain metastases or who fail first-line treatment.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- patients undergoing
- small cell lung cancer
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- early stage
- brain metastases
- metabolic syndrome
- adipose tissue
- skeletal muscle
- locally advanced
- machine learning
- electronic health record
- smoking cessation